KIDNEY CANCER

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…

This phase 2 trial tested the drug sunitinib in 21 patients with kidney cancer that had spread to the brain. The goal was to see if the drug could shrink brain tumors by blocking blood flow and cell growth. Researchers measured how many patients had a response after two treatment…

This study tested a combination of two immunotherapy drugs—high-dose interleukin-2 (IL-2) and pembrolizumab (Keytruda)—in 27 adults with metastatic kidney cancer. The goal was to see if the combination could shrink or eliminate tumors. Participants received both drugs in a coordi…

This study tested a new device that uses focused ultrasound (histotripsy) to break apart solid kidney tumors without making any cuts. Twenty adults with small, non-spreading kidney tumors were treated. The main goals were to see if the device could fully cover the tumor and if th…

This phase 3 trial tested whether the drug everolimus could prevent kidney cancer from coming back after surgery. Over 1,500 patients with high-risk kidney cancer took either everolimus or a placebo daily for 54 weeks. The study found a small improvement in recurrence-free surviv…

This study tested whether a simple breath test can predict if cancer patients will respond to immunotherapy drugs. Researchers used an electronic nose device to analyze breath samples from 190 patients with lung, melanoma, kidney, bladder, or head and neck cancers. The goal is to…

This study followed 623 adults in France with advanced kidney cancer who were starting treatment with the immunotherapy drugs nivolumab (with or without ipilimumab) for the first time. Unlike a clinical trial, this was an observational study that simply tracked what happened in e…

This study looked at how lifestyle factors like obesity and muscle loss affect kidney cancer risk and survival after kidney removal. Researchers collected blood, tissue, and questionnaire data from 161 patients over up to 5 years. The goal was to understand how to personalize tre…